A method for synthesis of nanoparticles are described. The method includes dispersing metal oxide powder in a mixture of a base liquid and a surfactant to form a primary mixture, grinding the primary mixture using a grinding media by periodically adding a surfactant solution to form a slurry, extracting a predetermined amount of sample from the slurry at periodic time intervals to obtain a testing solution to assess particle size of in the slurry using a particle size analyzer; and systematically adding the surfactant solution and the grinding media to the slurry based on the assessed particle size in the testing solution until a mean particle size of the nanoparticles is achieved.

To provide modified colloidal silica capable of improving the stability of the polishing speed with time when used as abrasive grains in a polishing composition for polishing a polishing object that contains a material to which charged modified colloidal silica easily adheres, such as a SiN wafer, and to provide a method for producing the modified colloidal silica. Modified colloidal silica, being obtained by modifying raw colloidal silica, wherein the raw colloidal silica has a number distribution ratio of 10% or less of microparticles having a particle size of 40% or less relative to a volume average particle size based on Heywood diameter (equivalent circle diameter) as determined by image analysis using a scanning electron microscope.

A method for producing mesoporous magnesium hydroxide nanoplates involving solvothermal treatment of a solution of a magnesium salt, a base, a glycol, and water is disclosed. The method does not use a surfactant or template in the solvothermal treatment. The method yields mesoporous nanoparticles of magnesium hydroxide having a plate-like morphology with a diameter of 20 nm to 100 nm, a mean pore diameter of 2 to 10 nm, a surface area of 50 to 70 m.sup.2/g, and a type-III nitrogen adsorption-desorption BET isotherm with a H3 hysteresis loop. An antibacterial composition containing the mesoporous magnesium hydroxide nanoplates is also disclosed. A method for reducing nitroaromatic compounds with a reducing agent and the mesoporous magnesium hydroxide nanoplates as a catalyst is also disclosed.

Zinc oxide powder of the present invention contains zinc oxide particles, in which primary particles of the zinc oxide particles have a minor axis of 35 nm or more and 350 nm or less and have a Heywood diameter of 35 nm or more and 400 nm or less, and a coefficient of variation of a number distribution of the Heywood diameters of the primary particles of the zinc oxide powder is 50% or less.

A process for making a mixed metal oxide, may involve: (a) providing a hydroxide or oxyhydroxide of TM with an average particle diameter (D50) in the range of from 0.1 μm to 5 mm; (b) subjecting the hydroxide or oxyhydroxide of TM to a stream of gas with a temperature in the range of from 150 to 2000° C., wherein TM contains nickel and at least one further transition metal selected from cobalt and manganese.

A solid electrolyte material contains Li, Y, at least one selected from the group consisting of Mg, Ca, Sr, Ba, Zn, Sc, La, Sm, Bi, Zr, Hf, Nb, and Ta, and at least one selected from the group consisting of Cl, Br, and I. An X-ray diffraction pattern of the solid electrolyte material obtained by using Cu-Kα radiation as the X-ray source includes peaks within the range in which the diffraction angle 2θ is 25° or more and 35° or less, and also includes at least one peak within the range in which the diffraction angle 2θ is 43° or more and 51° or less.

A solid electrolyte material contains Li; Y; at least one selected from the group consisting of Mg, Ca, Sr, Ba, Zn, Zr, Nb, and Ta; and at least one selected from the group consisting of Cl, Br, and I. An X-ray diffraction pattern of the solid electrolyte material obtained using Cu—Kα radiation as an X-ray source includes peaks in a range of diffraction angles 2θ of 30° or more and 33° or less, in a range of diffraction angles 2θ of 39° or more and 43° or less, and in a range of diffraction angles 2θ of 47° or more and 51° or less.

The invention relates to a strontium aluminate mixed oxide precursor and a method for producing same, as well as to a strontium aluminate mixed oxide and method for producing same. The strontium aluminate mixed oxide precursor can be transformed into a strontium aluminate mixed oxide at relatively low temperature. The strontium aluminate mixed oxide is characterized by substantially spherically-shaped particles with a spongy- or porous bone-like microstructure. A luminescent material including a strontium aluminate mixed oxide is also provided.

The positive electrode active material has high capacity and high output and exhibiting excellent cycle characteristics when being used for a positive electrode of a non-aqueous electrolyte secondary battery. A positive electrode active material for a lithium ion secondary battery contains: a lithium-metal composite oxide containing secondary particles with a plurality of aggregated primary particles; and a compound containing lithium and tungsten present on surfaces of the primary particles. The amount of tungsten contained in the compound containing lithium and tungsten is 0.5 atom % or more and 3.0 atom % or less in terms of a ratio of the number of atoms of W with respect to the total number of atoms of Ni, Co, and an element M, and a conductivity when the positive electrode active material is compressed to 4.0 g/cm.sup.3 as determined by powder resistance measurement is 6×10.sup.−3 S/cm or less.

Provided is a medical calcium carbonate composition that highly satisfies 1) tissue affinity, 2) in vivo resorbability, 3) reactivity, and 4) mechanical strength required for medical materials to be implanted in vivo, a medical calcium phosphate composition, a medical carbonate apatite composition, a medical calcium hydroxide porous structure, a medical calcium sulfate setting granules, and a bone defect regeneration kit related to the medical calcium carbonate composition, and methods for producing these. The medical composition calcium carbonate that highly satisfies the above described elements, and related medical compositions can be produced by controlling the polymorph or structure of calcium carbonate.